Part 1: Current Approach to Treating Chronic Myeloid Leukemia

Jack W. Erter, III, MD, and Ramiro Garzon, MD

Drs. Erter and Garzon are fellows; both are at the Division of Hematology/Oncology, Comprehensive Care Center, Ohio State University, Columbus, OH.

Question 1

Which of the following is not an indication for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with chronic myeloid leukemia (CML) in the chronic phase?

  •  Cytogenetic relapse at 18 months after achieving initial
    hematologic remission
  •  First-line treatment in a chronic-phase CML (CP-CML) patient
  •  No cytogenetic response at 6 months
  •  Partial cytogenetic response at 18 months
  •  Presence of T571 mutation in patients who failed to respond
    to tyrosine kinase inhibitors (TKIs)

Updated 3/4/2009 • nvf | Copyright ©2009 Turner White Communications